Century Therapeutics, Inc. Defined Contribution Plan, Cost
Century Therapeutics, Inc. (IPSC) reported Defined Contribution Plan, Cost of $135.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-08-12
- Century Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2026-06-30 was $135.00K, a 41.81% decline year-over-year.
- Century Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2026-03-31 was $240.00K, a 39.55% decline year-over-year.
- Century Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2025-06-30 was $232.00K.
- Century Therapeutics, Inc. defined contribution plan, cost for the quarter ending 2025-03-31 was $397.00K.
- Century Therapeutics, Inc. defined contribution plan, cost for fiscal 2025 was $1.01M, a 10.97% decline from fiscal 2024.
- Century Therapeutics, Inc. defined contribution plan, cost for fiscal 2024 was $1.13M, a 12.20% decline from fiscal 2023.
- Century Therapeutics, Inc. defined contribution plan, cost for fiscal 2023 was $1.29M, a 49.30% increase from fiscal 2022.
- Century Therapeutics, Inc. defined contribution plan, cost for fiscal 2022 was $862.00K, a 60.82% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $135.00K 10-Q · filed 2026-08-12 | $375.00K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $240.00K 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.01M 10-K · filed 2026-03-12 | |||
| 2025-06-30 | $232.00K 10-Q · filed 2026-08-12 | $629.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $397.00K 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $1.13M 10-K · filed 2026-03-12 | |||
| 2023-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $674.00K derived: sum of 2 quarters · filed 2025-03-19 | $903.00K derived: sum of 3 quarters · filed 2025-03-19 | $1.29M 10-K · filed 2025-03-19 |
| 2023-09-30 | $514.00K 10-Q · filed 2023-11-09 | $743.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.13M 10-Q · filed 2023-11-09 | $1.34M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-06-30 | $229.00K 10-Q · filed 2023-08-09 | $613.00K 10-Q · filed 2023-08-09 | $831.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.08M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-03-31 | $384.00K 10-Q · filed 2023-05-11 | $602.00K derived: sum of 2 quarters · filed 2024-03-14 | $851.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.09M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $467.00K derived: sum of 2 quarters · filed 2024-03-14 | $704.00K derived: sum of 3 quarters · filed 2024-03-14 | $862.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $249.00K 10-Q · filed 2023-11-09 | $486.00K derived: sum of 2 quarters · filed 2023-11-09 | $644.00K 10-Q · filed 2023-11-09 | $731.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $237.00K 10-Q · filed 2023-08-09 | $395.00K 10-Q · filed 2023-08-09 | $482.00K derived: sum of 3 quarters · filed 2023-08-09 | $570.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $158.00K 10-Q · filed 2023-05-11 | $245.00K derived: sum of 2 quarters · filed 2023-05-11 | $333.00K derived: sum of 3 quarters · filed 2023-05-11 | $482.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $175.00K derived: sum of 2 quarters · filed 2023-03-16 | $324.00K derived: sum of 3 quarters · filed 2023-03-16 | $536.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $88.00K 10-Q · filed 2022-11-10 | $237.00K derived: sum of 2 quarters · filed 2022-11-10 | $449.00K 10-Q · filed 2022-11-10 | $533.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $149.00K 10-Q · filed 2022-08-11 | $361.00K 10-Q · filed 2022-08-11 | $445.00K derived: sum of 3 quarters · filed 2022-08-11 | $527.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $212.00K 10-Q · filed 2022-05-16 | $296.00K derived: sum of 2 quarters · filed 2022-05-16 | $378.00K derived: sum of 3 quarters · filed 2022-05-16 | $450.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $166.00K derived: sum of 2 quarters · filed 2022-03-17 | $238.00K derived: sum of 3 quarters · filed 2022-03-17 | $301.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $82.00K 10-Q · filed 2021-11-10 | $154.00K derived: sum of 2 quarters · filed 2021-11-10 | $217.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $72.00K 10-Q · filed 2021-08-12 | $135.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |